|Advanced Life Sciences Holdings, Inc.|
1440 Davey Road
United States - Map
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs in the therapeutic areas of infection, oncology, and respiratory disease. The companys lead product candidate includes Restanza, a once-a-day oral antibiotic for the treatment of respiratory tract infections, including community acquired bacterial pneumonia and biodefense pathogens, such as anthrax, plague, and tularemia. It is also developing ALS-357, a compound for the topical treatment of malignant melanoma; and ALS-886, a therapeutic for the treatment of inflammation-related tissue damage consisting of tissue damage associated with acute respiratory distress syndrome. The company has collaboration agreements with Abbott Laboratories to develop and commercialize cethromycin; University of Illinois to develop, make, use, and sell ALS-357 and related compounds; and Baxter International, Inc. Advanced Life Sciences Holdings, Inc. was founded in 1999 and is headquartered in Woodridge, Illinois.
|Dr. Michael T. Flavin Ph.D.,
Founder, Chairman and Chief Exec. Officer
|Mr. John L. Flavin ,
Pres, Chief Financial Officer, Principal Accounting Officer, Sec. and Director
|Dr. Ze-Qi Xu Ph.D.,
Chief Scientific Officer, Exec. VP and Sec. of Advanced Life Sciences Inc
|Mr. Patrick W. Flavin J.D.,
Chief Legal Counsel
|Dr. Suseelan Pookote Ph.D.,
Exec. VP of Corp. Devel.
|Amounts are as of Dec 31, 2010 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|